InflaRx (IFRX) Q4 2025 earnings summary

Executive summary

• Positive Phase 2a data for izicopan in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) support its potential as a differentiated, effective, and safe oral C5aR inhibitor.

• Strategic focus shifted to izicopan, with ongoing FDA discussions for Phase 2b trial design in HS and plans to expand into additional inflammation and immunology (I&I) indications.

• Significant cost reductions implemented, extending projected cash runway to mid-2027.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled €46.2 million as of December 31, 2025.

• Net loss for 2025 was €45.6 million (€0.68 per share), compared to €46.1 million (€0.78 per share) in 2024.

• Research and development expenses decreased by €9.6 million year-over-year, mainly due to lower third-party and clinical trial costs.

• Marketing and sales expenses decreased by €2.3 million year-over-year, reflecting reduced commercial activity.

• Net cash used in operating activities was €35.3 million, down from €48.6 million in 2024.

Outlook and guidance

• Complete Phase 2a results for izicopan expected at major scientific meetings in 2026.

• Virtual Capital Markets Day planned to detail izicopan's clinical development path and market opportunities.

• Ongoing evaluation of izicopan for additional I&I indications, including ANCA-associated vasculitis (AAV) and CSU.

• PK bridging study in China planned to expedite proof-of-concept studies.